Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05208944
Title A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab in Subjects With Advanced NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Maia Biotechnology
Indications
Therapies
Age Groups: adult | senior
Covered Countries POL | HUN | BGR | AUS


No variant requirements are available.